Cerenome is trading at $0.73, up 8.97% in pre-market; no fresh company-specific catalyst was identified for the November 6 move.
- The November 4 Aetna agreement is prior news, not a clear new catalyst.
- Nasdaq futures rose after Thursday’s technology selloff, with chip shares rebounding, providing a potentially supportive broader backdrop.
- The gain follows sharp declines in recent sessions; no volume or trading-activity data was verified.